New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:55 EDTBAX, BAX, BAYRY, BAYRY, BIIB, BIIB, PBTH, PBTH, NVO, NVOLeerink's biotech analyst holds an analyst/industry conference call
Biotech Analyst Schimmer discusses the outlook for long-acting factor replacements in hemophilia on an Analyst/Industry conference call. Relevant covered companies BAX, BAYRY, BIIB, PBTH and NVO may be included on the Analyst/Industry conference call to be held on March 29 at 2 pm.
News For BAX;BAYRY;BIIB;PBTH;NVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
07:29 EDTBAXMarcus Evans to hold a conference
4th Annual Medical Device Safety Monitoring & Reporting Conference is being held in Las Vegas on November 27-28.
November 24, 2015
05:34 EDTBIIBSobi, Biogen announce approval of Elocta in Europe
Subscribe for More Information
November 20, 2015
07:17 EDTBIIBBiogen says Benepali receives 'positive' opinion from CHMP
Subscribe for More Information
November 18, 2015
06:03 EDTBAYRYBayer says not looking to sell crop chemicals business, Reuters reports
Bayer (BAYRY) says its Bayer CropScience unit is an "integral part" of the company and that the division is not for sale, Reuters reports. Bayer's comments come after Monsanto (MON) executives said that it is in internal discussions about tie-ups in the industry. Reference Link
November 16, 2015
06:11 EDTBAXBaxter resumed with a Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Brooks West downgraded Baxter (BAX) to Neutral after resuming coverage of the name. The company, post the spin of Baxalta (BXLT), "has a number of moving pieces that need to be addressed," West tells investors in a research note. He lowered his price target for shares to $39 from $90.
November 15, 2015
13:04 EDTBAYRYBayer shares could advance 25% in a year, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use